life
cycl
human
immunodefici
viru
type
absolut
requir
ribosom
frameshift
protein
translat
order
produc
polyprotein
precursor
viral
enzym
rna
stemloop
structur
frameshift
stimul
signal
fss
control
frameshift
effici
hypothes
attract
therapeut
target
develop
compound
select
bind
rna
interfer
replic
proven
challeng
build
prior
discoveri
hit
molecul
abl
bind
stemloop
report
develop
compound
display
high
affin
fss
compound
abl
enhanc
frameshift
dualluciferas
assay
human
embryon
kidney
cell
strongli
inhibit
infect
pseudotyp
virion
error
repres
standard
error
global
fit
least
five
sensorgram
compound
inject
repeat
twice
concentr
verifi
consist
data
compound
ref
condit
hb
buffer
hepe
nacl
ph
b
mm
hepe
mm
nacl
mm
mgcl
human
immunodefici
viru
type
caus
agent
acquir
immun
defici
syndrom
aid
remain
signific
challeng
global
health
sinc
initi
identif
infect
reach
statu
pandem
alon
approxim
million
new
infect
million
death
aid
relat
caus
current
cure
infect
progress
diseas
control
highli
activ
antiretrovir
therapi
haart
combin
drug
design
inhibit
differ
stage
viru
life
cycl
complex
haart
regimen
abil
viru
evolv
resist
suggest
altern
drug
target
treatment
prophylaxi
need
one
potenti
attract
target
pharmacolog
interfer
life
cycl
viru
requir
program
ribosom
frameshift
prf
order
express
enzym
ribosom
frameshift
recod
mechan
common
among
virus
polycistron
multipl
open
read
frame
orf
singl
gene
genom
allow
virus
translat
polypeptid
differ
orf
avoid
stop
codon
present
singl
mrna
transcript
pol
gene
read
frame
respect
gag
gag
precusor
viral
structur
protein
produc
via
normal
translat
rule
pol
precursor
viral
enzym
synthes
fuse
gagpol
polyprotein
via
prf
occur
frequenc
ribosom
translat
fulllength
viral
mrna
critic
molar
ratio
gagpol
gag
protein
requir
replic
infect
alter
ratio
shown
detriment
prf
control
two
ci
act
mrna
element
heptamer
slipperi
sequenc
u
uuu
uua
frame
indic
space
frameshift
actual
occur
downstream
twostem
helix
immedi
follow
slipperi
sequenc
also
known
frameshift
stimulatori
signal
fss
figur
sever
mechan
propos
account
frameshift
current
hypothes
event
result
incomplet
transloc
limit
number
ribosom
due
resist
fss
unwind
ribosom
start
translat
pol
new
read
frame
modif
slipperi
site
stimulatori
sequenc
either
via
natur
variat
laboratori
mutat
way
affect
frameshift
effici
translat
decreas
viral
replic
result
led
sever
group
propos
prf
potenti
target
develop
antiretrovir
agent
nmr
structur
analys
indic
fss
rna
consist
gc
rich
upper
stemloop
structur
separ
flexibl
lower
stem
gga
trinucleotid
bulg
figur
bulg
produc
roughli
upper
lower
stem
upper
stemloop
except
stabl
stabil
believ
play
vital
role
stimul
frameshift
sinc
ribosom
must
unwind
stem
translat
lower
stem
thermodynam
less
stabl
highli
structur
acaa
tetraloop
uncommon
among
tetraloop
conserv
among
group
subtyp
except
uncommon
h
j
subtyp
likewis
heptamer
slipperi
sequenc
conserv
across
group
subtyp
shape
analysi
intact
hiv
genom
suggest
complex
structur
fss
rna
although
upper
stemloop
retain
sinc
virus
also
reli
frameshift
target
frameshiftregul
structur
may
gener
util
beyond
context
hiv
exampl
human
tcell
leukemia
viru
type
use
two
prf
event
similar
order
synthes
fuse
gagpro
gagpropol
precursor
protein
rna
respons
prf
essenti
express
gagpro
also
consist
two
cisact
rna
element
heptanucleotid
aaaaaac
slipperi
site
stemloop
shown
figur
fss
serv
sequenc
specif
control
experi
describ
herein
first
attempt
use
synthet
molecul
alter
frameshift
therebi
influenc
viral
replic
report
green
cowork
author
show
n
ndimethylpropyl
amidino
benzen
tetrahydrochlorid
bi
guanidiniumcontain
compound
term
abl
stimul
frameshift
alter
gagpol
gag
ratio
inhibit
replic
cem
cell
lymphocyt
cell
line
interfer
format
viral
particl
chronic
infect
cell
co
cell
line
stabli
transfect
hivgpt
hiv
deriv
e
coli
gpt
gene
replac
hiv
env
increas
revers
transcriptas
rt
follow
treatment
mm
also
observ
would
expect
increas
gagpol
product
recent
butcher
group
confirm
compound
inde
bind
fss
rna
weak
affin
k
carri
nmr
structur
analysi
indic
bind
major
groov
upper
stemloop
unfortun
note
author
rel
nonselect
binder
interact
rna
stimul
frameshift
virus
differ
fss
like
also
interact
ribosom
also
toxic
like
result
lack
select
moreov
interfer
hiv
replic
begin
concentr
observ
affect
frameshift
compound
guanidinoneomycin
idarubicin
doxorubicin
shown
bind
fss
doxorubicin
found
bind
k
decreas
frameshift
rabbit
reticulocyt
assay
also
significantli
reduc
overal
translat
screen
argrich
peptid
librari
reveal
sequenc
abl
significantli
reduc
frameshift
display
select
fss
rel
frameshiftstimul
construct
like
also
interact
ribosom
thu
far
awar
report
exampl
synthet
molecul
abl
alter
frameshift
interfer
viral
infect
via
select
highaffin
bind
fss
rna
build
laboratori
longstand
interest
understand
factor
drive
affin
sequenc
select
small
molecul
recognit
rna
previous
report
use
resinbound
dynam
combinatori
librari
design
base
structur
dnabind
bisintercal
peptid
antibiot
identifi
compound
abl
bind
fss
upper
stemloop
moder
affin
k
immobil
surfac
plasmon
reson
spr
chip
via
one
amin
group
k
nm
solut
measur
fluoresc
good
select
subsequ
effort
reveal
replac
disulfid
bridg
olefin
produc
compound
could
accomplish
without
reduct
affin
studi
also
indic
affin
essenti
abolish
area
molecul
reduc
peptid
portion
requir
sequenceselect
bind
right
fss
stemloop
sequenc
use
specif
control
work
note
slipperi
sequenc
occupi
decod
site
ribosom
lower
stem
unwound
upper
stemloop
act
effect
frameshift
stimulatori
signal
bind
abil
intrigu
subsequ
preliminari
experi
indic
compound
unabl
inhibit
viru
pseudotyp
assay
data
shown
given
result
hypothes
increas
affin
essenti
anticip
increas
surfac
area
could
repres
viabl
strategi
enhanc
affin
fss
without
signific
reduct
select
particular
incorpor
benzo
g
quinolin
moieti
produc
view
attract
hypothesi
support
part
parallel
effort
laboratori
design
synthesi
compound
target
cug
repeat
rna
incorpor
benzo
g
quinolin
found
enhanc
affin
provid
compound
activ
vivo
mous
model
type
myoton
dystrophi
synthesi
proceed
via
crossmetathesi
halfstructur
analog
previou
work
also
synthes
onearm
benzo
g
quinolinebear
structur
well
compound
test
effect
sequenti
remov
put
intercal
compound
synthes
order
ascertain
effect
olefin
bioisoster
improv
cellular
avail
bioactiv
rel
easili
reduc
disulfid
synthes
compound
first
analyz
bind
fss
surfac
plasmon
reson
spr
techniqu
allow
equilibrium
constant
k
kinet
rate
constant
k
k
determin
labelfre
format
label
fss
rna
upper
stemloop
sequenc
figur
immobil
streptavidinfunction
sensor
chip
compound
solut
hb
buffer
hepe
nacl
ph
flow
rna
referencesubtract
sensorgram
record
associ
dissoci
phase
experiment
sensorgram
least
five
differ
concentr
global
fit
langmuir
equat
obtain
bind
constant
condit
benzo
g
quinolinecontain
compound
bound
fss
affin
k
nm
nm
respect
case
repres
approxim
increas
affin
tabl
bind
benzo
g
quinolin
contain
monom
weaker
rel
dimer
remov
one
heterocycl
arm
also
result
approxim
decreas
affin
decreas
remov
benzo
g
quinolin
group
complet
abrog
bind
fss
rna
consist
prior
result
indic
import
heterocycl
group
affin
disulfid
link
compound
bound
target
rna
k
weaker
rel
olefin
analog
bind
observ
benzo
g
quinolin
carboxyl
acid
spr
confirm
anticip
select
fss
compound
show
bind
fss
spr
concentr
support
inform
p
dissoci
phase
spr
trace
obtain
highest
concentr
compound
well
fit
singleexponenti
function
control
possibl
compound
aggreg
interf
measur
therefor
reexamin
compound
use
run
buffer
contain
deterg
mm
hepe
mm
nacl
mm
mgcl
margin
impact
fit
kinet
paramet
tabl
suggest
aggreg
signific
complic
factor
assay
spr
chip
low
densiti
rna
provid
similar
dissoci
constant
support
inform
confirm
thermodynam
dissoci
constant
measur
spr
fulli
solutionphas
method
assess
sequenc
select
fluoresc
titrat
conduct
experi
satur
quench
benzo
g
quinolin
fluoresc
observ
function
ad
unlabel
rna
dissoci
constant
obtain
manner
tabl
bind
fss
rna
gener
agreement
obtain
via
spr
fluoresc
observ
select
bind
fss
rna
vs
total
yeast
trna
select
fss
rna
vs
fss
dna
select
fss
rna
vs
trna
somewhat
lower
curious
unlik
select
fss
rna
vs
fss
dna
thu
previous
found
measur
affin
trna
conclud
increas
affin
obtain
replac
quinolin
moieti
benzo
g
quinolin
come
cost
decreas
select
result
contrast
observ
relat
seri
compound
optim
bind
triplet
repeat
rna
sequenc
relev
type
myoton
dystrophi
like
differ
structur
foundat
experi
need
explor
hypothesi
cell
permeat
toxic
analyz
effect
compound
frameshift
cell
verifi
capabl
cross
cell
membran
toxic
reason
concentr
human
embryon
kidney
cell
hek
treat
concentr
h
cell
wash
use
standard
method
ensur
cell
stain
simpli
due
surfac
captur
inher
fluoresc
benzo
g
quinolin
chromophor
compound
allow
direct
visual
cell
penetr
via
fluoresc
microscopi
figur
show
result
treatment
addit
imag
provid
support
inform
confirm
cell
intern
three
compound
compound
appear
local
specif
cell
viabil
analyz
use
assay
compound
incub
hek
cell
cultur
dmem
h
media
cell
prolifer
reagent
mixtur
replac
growth
media
h
absorb
measur
nm
disulfid
link
compound
prove
toxic
concentr
signific
toxic
compound
occur
concentr
figur
higher
toxic
observ
rel
surpris
like
reflect
labil
disulfid
bond
reduc
environ
cell
compound
next
evalu
abil
alter
fssdepend
frameshift
use
dualluciferas
report
assay
system
fss
sequenc
insert
renilla
rluc
firefli
fluc
luciferas
gene
sever
construct
employ
pdualhiv
construct
fluc
read
frame
rel
rluc
pdualhiv
construct
fluc
read
frame
rel
rluc
case
fluc
express
fuse
rlucfluc
protein
case
pdualhiv
frameshift
requir
ascertain
compounddepend
effect
frameshift
specif
also
carri
analog
prf
assay
use
construct
frameshift
site
insert
rluc
fluc
gene
fluc
synthes
event
hek
cell
transient
transfect
separ
pdualhiv
pdualhiv
plasmid
frameshift
effici
defin
ratio
firefli
renilla
luciferas
activ
pdualhiv
transfect
cell
measur
presenc
vari
concentr
compound
statist
signific
p
dosedepend
increas
fluc
rluc
ratio
observ
follow
treatment
figur
control
compound
show
measur
bind
fss
spr
signific
effect
prf
pdualhiv
transfect
cell
similar
condit
hek
cell
transfect
pdualhiv
plasmid
fuse
renillafirefli
luciferas
protein
synthes
convent
translat
rule
ie
without
ribosom
frameshift
therefor
confirm
observ
effect
pdualhiv
cell
direct
effect
compound
frameshiftdepend
translat
pdualhiv
transfect
cell
treat
analog
compound
chang
fluc
rluc
ratio
rel
untreat
pdualhiv
transfect
hek
cell
observ
suggest
specif
stimul
frameshift
translat
cell
disulfid
link
stimul
frameshift
approxim
support
inform
lower
effect
compar
case
consist
lower
affin
fss
like
labil
cell
treatment
hek
transfect
construct
compound
result
chang
flucrluc
ratio
compar
case
untreat
cell
consist
vitro
spr
result
bind
observ
compound
fss
rna
compound
decreas
viral
infect
order
observ
frameshift
effect
compound
signific
import
correl
equival
reduct
viral
replic
assess
analyz
effect
compound
singleround
infect
pseudotyp
hiv
hek
produc
cell
tzmbl
target
cell
hela
cell
line
wild
type
hiv
provir
vector
code
gene
except
nef
replac
gfp
env
thu
preserv
gag
pol
frameshift
requir
product
gagpol
polyprotein
preliminari
experi
show
activ
assay
howev
observ
statist
signific
p
concentrationdepend
decreas
infect
pseudotyp
virion
produc
cell
treat
figur
decreas
infect
concentr
concentr
core
peptid
alon
show
modest
decreas
infect
concentr
compound
increas
frameshift
dualluciferas
assay
incorpor
fss
effect
frameshift
analog
assay
incorpor
fss
rel
frameshift
effici
hek
cell
treat
control
peptid
transfect
pdualhiv
frameshift
effici
calcul
ratio
fluc
rluc
pdualhiv
transient
transfect
cell
ratio
arbitrarili
set
plasmidtransfect
cell
expos
compound
error
sem
three
replic
concentr
like
via
nonspecif
effect
given
lack
affin
fss
ec
valu
respect
proteas
inhibitor
indinavir
test
parallel
calibr
assay
ec
found
nm
line
previous
report
valu
viru
titer
determin
experi
use
elisa
assay
normal
viral
load
target
cell
compounddepend
decreas
viral
product
also
readili
observ
via
fluoresc
microscopi
pseudotyp
hiv
carri
gfp
marker
figur
phasecontrast
imag
cell
show
morpholog
chang
consist
result
support
inform
concentr
rang
requir
decreas
viral
infect
similar
rang
signific
increas
frameshift
observ
hek
ft
cell
support
hypothesi
compound
exert
antivir
activ
primarili
alter
prf
order
provid
support
hypothesi
viral
particl
isol
supernat
experi
spin
sucros
cushion
probe
via
western
blot
presenc
revers
transcriptas
rt
rt
produc
part
gagpol
fusion
increas
amount
rt
rel
capsid
protein
structur
protein
produc
part
gag
would
requir
given
increas
frameshift
inde
observ
function
ad
figur
amount
rt
unprocess
gagpol
rel
matur
rt
also
increas
significantli
may
indic
treatment
compound
also
inhibit
pol
process
howev
pattern
cleavag
intermedi
observ
design
small
molecul
target
specif
rna
sequenc
elicit
desir
rna
mediat
biolog
respons
constitut
one
signatur
challeng
chemic
biolog
paper
demonstr
moderateaffin
hit
compound
fss
rna
obtain
resinbound
dynam
combinatori
librari
screen
transform
highaffin
binder
intrigu
observ
initi
screen
find
symmetr
compound
select
despit
target
rna
nonsymmetr
work
confirm
put
intercal
requir
highaffin
bind
compound
weak
affin
fss
structur
analysi
essenti
fulli
understand
bind
mode
recognit
nonsymmetr
rna
bind
site
symmetr
dimer
molecul
unpreced
exampl
arya
colleagu
describ
use
neomycin
dimer
recognit
hiv
tar
rna
hergenroth
group
design
deoxystreptamin
dimer
bound
nonsymmetr
rna
loop
likewis
structur
inform
prove
use
understand
significantli
higher
select
fss
rna
fss
dna
trna
rel
enhanc
compound
abl
alter
frameshift
dual
luciferas
assay
hek
cell
strongli
inhibit
viral
infect
pseudotyp
hiv
assay
rel
previous
studi
compound
target
frameshift
hiv
compound
produc
roughli
equival
increas
rt
lower
concentr
compound
repres
promis
lead
studi
well
interest
tool
investig
mechan
prf
sinc
pseudotyp
hiv
use
assay
capabl
one
round
replic
anticip
stronger
effect
observ
wildtyp
hiv
spread
infect
assay
cours
enhanc
affin
select
would
like
improv
activ
well
discuss
previou
highthroughput
screen
effort
target
frameshiftmodul
compound
bicistron
report
provid
assay
readout
larg
yield
compound
act
ribosom
given
observ
suggest
other
assay
focus
direct
bind
fss
rna
could
advantag
compound
could
potenti
increas
frameshift
inhibit
unwind
upper
stemloop
result
present
herein
support
hypothesi
context
hiv
biolog
result
compound
indic
increas
frameshift
concomit
increas
gagpolgag
ratio
decreas
viral
fit
consist
work
mak
colleagu
increas
gagpolgag
ratio
via
cotransfect
experiment
section
reagent
commerci
avail
reagent
obtain
sigmaaldrich
chemic
co
st
loui
mo
tci
america
portland
fisher
scientif
emd
chemic
gibbstown
nj
advanc
chemtech
louisvil
ky
alfa
aesar
use
without
purif
unless
otherwis
note
water
use
reaction
aqueou
workup
glassdistil
deioniz
water
feed
reagent
grade
solvent
use
nonaqu
extract
reaction
progress
monitor
analyt
thinlay
chromatographi
tlc
use
em
silica
gel
precoat
glass
plate
mm
compound
visual
tlc
plate
uv
lamp
dual
wavelength
nm
nm
synthes
compound
purifi
use
flash
column
chromatographi
em
silica
gel
mesh
altern
via
prepar
revers
phase
hplc
cell
cultur
dulbecco
modifi
eagl
medium
dmem
supplement
fb
streptomycin
premix
cell
prolifer
reagent
purchas
clontech
luminesc
assay
carri
use
promega
dualluciferas
assay
kit
follow
manufactur
instruct
analysi
h
nmr
spectra
record
either
bruker
avanc
mhz
bruker
avanc
mhz
instrument
process
use
mestrenova
nmr
process
softwar
chemic
shift
report
part
per
million
ppm
downfield
tetramethylsilan
referenc
residu
protium
signal
nmr
solvent
data
report
follow
chemic
shift
multipl
singlet
doublet
triplet
multiplet
q
quartet
coupl
constant
j
hertz
hz
integr
c
spectra
record
bruker
avanc
instrument
oper
mhz
chemic
shift
report
ppm
downfield
tetramethylsilan
referenc
except
primari
carbon
reson
nmr
solvent
ftir
spectra
record
shimadzu
ftir
spectrophotomet
highresolut
mass
spectra
hrm
acquir
univers
buffalo
chemistri
depart
mass
spectrometri
facil
buffalo
ny
synthesi
compound
compound
synthes
follow
procedur
analog
previous
report
compound
produc
puriti
determin
analyt
hplc
briefli
synthes
olefin
precursor
monom
assembl
wang
resin
standard
fmoc
solid
phase
peptid
synthesi
spp
method
one
half
resinbound
monom
cleav
use
tfa
dcm
te
use
solut
phase
partner
olefin
metathesi
reaction
employ
grubb
second
gener
catalyst
olefin
product
isom
ratio
ze
isol
use
revers
phase
hplc
column
water
xbridg
prep
obd
mm
mm
use
gradient
elut
tfa
tfa
olefin
geometri
assign
compar
olefin
proton
chemic
shift
eolefin
downfield
zisom
also
infrar
spectra
compound
describ
previous
figur
compound
affect
gag
gagpol
ratio
pseudotyp
virion
equal
load
viral
particl
measur
elisa
isol
media
viral
produc
cell
spin
sucros
cushion
viral
particl
western
blot
rt
abcam
nih
aid
reagent
program
cat
densitometri
nonsatur
band
use
calcul
ratio
list
rt
blot
ratio
total
band
list
blot
compound
synthes
slight
modif
procedur
describ
tripeptid
pheproallylgli
first
assembl
use
fmoc
peptid
coupl
chemistri
wang
resin
resinbound
tripeptid
separ
two
equal
part
benzo
g
quinolin
carboxyl
acid
coupl
half
materi
cleav
tfa
employ
solut
phase
compon
olefin
crossmetathesi
remain
beadbound
portion
fmocprotect
tripeptid
surfac
plasmon
reson
spr
bind
analysi
surfac
plasmon
reson
spr
experi
perform
biacorex
instrument
biacor
inc
uppsala
sweden
sensor
chip
approxim
ru
streptavidin
rockland
immunochem
immobil
flow
cell
use
edcnh
chemistri
either
nm
fss
nm
fss
rna
sequenc
obtain
commerci
integr
dna
technolog
inc
captur
onto
streptavidin
surfac
one
flow
cell
densiti
approxim
ru
streptavidin
surfac
second
flow
cell
block
biotin
solut
serv
refer
cell
correct
nonspecif
bind
bind
constant
measur
carri
compound
low
densiti
approxim
ru
chip
highdens
approxim
ru
chip
order
ensur
bind
influenc
rna
densiti
kinet
bind
experi
carri
flow
variou
concentr
compound
hb
buffer
hepe
nacl
ph
per
min
flow
rate
b
mm
hepe
mm
nacl
mm
mgcl
per
min
flow
rate
captur
rna
sequenc
necessari
aqueou
nacl
inject
suffici
regener
compound
display
fast
offrat
requir
regener
chip
inject
bind
constant
obtain
global
fit
condit
associ
dissoci
phase
least
five
referencedsubtract
blankcorrect
sensorgram
langmuir
bind
equat
via
individu
fit
condit
b
use
biaevalu
softwar
inject
concentr
repeat
least
twice
consist
fluoresc
titrat
fluoresc
titrat
carri
mm
hepe
mm
nacl
use
cari
eclips
spectrofluoromet
titrat
start
volum
compound
rna
titrat
highconcentr
stock
fss
rna
fss
dna
trna
increment
rna
ad
solut
thoroughli
mix
cuvett
via
pipet
allow
stand
min
reach
equilibrium
measur
taken
three
time
min
wait
period
scan
confirm
equilibrium
reach
intens
correct
dilut
cell
permeat
hek
cell
grown
confluenc
co
expos
compound
concentr
h
tissu
cultur
plate
remov
cultur
media
dmem
contain
fb
penicillinstreptomycin
gibco
cell
wash
twice
pb
remov
excess
surfacebound
compound
cell
imag
buffer
fluoresc
microscop
olympu
plate
use
excit
emiss
filter
cell
toxic
hek
ft
cell
plate
tissu
cultur
plate
dmem
fetal
bovin
serum
penicillinstreptomycin
allow
grow
confluenc
co
vari
compound
concentr
mm
control
ident
volum
steril
h
triplic
incub
cell
h
ten
microlit
premix
cell
prolifer
reagent
clontech
ad
well
includ
blank
dmem
follow
h
incub
absorb
measur
nm
subtract
blank
correct
differ
absorb
plot
compound
concentr
dualluciferas
report
frameshift
assay
cell
hek
cell
plate
plate
densiti
cellswel
h
transfect
dmem
fetal
bovin
serum
penicillinstreptomycin
cell
transient
transfect
separ
well
plasmid
dna
pdualhiv
pdualhiv
use
lipofectamin
transfect
reagent
invitrogen
follow
manufactur
protocol
five
hour
transfect
variou
compound
concentr
ad
directli
cell
triplic
incub
h
cultur
media
gentli
aspir
wash
pb
lyse
passiv
lysi
buffer
rluc
fluc
activ
measur
cell
lysat
luciferas
reagent
use
dualluciferas
assay
system
promega
well
fluc
rluc
luminesc
valu
measur
modulu
micropl
reader
turner
biosystem
rel
frameshift
effici
calcul
compar
flucrluc
luminesc
ratio
cell
treat
compound
untreat
cell
infect
assay
antivir
activ
measur
singleround
infect
assay
pseudotyp
use
produc
cell
provir
vector
code
gene
except
nef
replac
gfp
env
thu
preserv
gag
pol
frameshift
requir
product
gagpol
polyprotein
singleround
infect
assay
conduct
transient
transfect
viral
vector
vsvg
coat
protein
vector
ratio
use
fugen
hd
promega
viru
produc
cell
dose
compound
four
hour
transfect
viral
particl
harvest
media
h
transfect
filter
syring
filter
viral
load
normal
elisa
perkinelm
infect
perform
use
tzmbl
report
cell
contain
stabli
integr
firefli
luciferas
driven
hivltr
promot
therefor
luciferas
express
upon
success
hiv
infect
triplic
infect
plate
cellswel
pg
proceed
h
addit
steadyglo
reagent
promega
well
min
luminesc
measur
quantit
metric
chang
viral
infect
presenc
compound
